In general, gliomas are more common in industrialized countries and among white people. There is a slight male predominance; glioblastoma incidence rate is 1.6-fold higher in men than in women.[3]Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022 Oct 5;24(5 suppl):v1-95.
https://academic.oup.com/neuro-oncology/article/24/Supplement_5/v1/6742201
http://www.ncbi.nlm.nih.gov/pubmed/36196752?tool=bestpractice.com
[4]Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185005
http://www.ncbi.nlm.nih.gov/pubmed/25053711?tool=bestpractice.com
Circumscribed gliomas (pilocytic/pilomyxoid astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma) have a combined annual incidence of less than 1 in 100,000 people.[3]Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022 Oct 5;24(5 suppl):v1-95.
https://academic.oup.com/neuro-oncology/article/24/Supplement_5/v1/6742201
http://www.ncbi.nlm.nih.gov/pubmed/36196752?tool=bestpractice.com
Pilocytic astrocytomas of the optic pathway are associated with neurofibromatosis type 1.[5]Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007 Feb;44(2):81-8.
https://jmg.bmj.com/content/44/2/81.long
http://www.ncbi.nlm.nih.gov/pubmed/17105749?tool=bestpractice.com
Subependymal giant cell astrocytomas are a manifestation of tuberous sclerosis complex.[6]Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021 Oct;123:50-66.
https://www.pedneur.com/article/S0887-8994(21)00151-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34399110?tool=bestpractice.com
Glioblastoma is the most common primary brain tumor, with an annual incidence in the US of 3-4 cases per 100,000 people. Median age at diagnosis is 65 years.[3]Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022 Oct 5;24(5 suppl):v1-95.
https://academic.oup.com/neuro-oncology/article/24/Supplement_5/v1/6742201
http://www.ncbi.nlm.nih.gov/pubmed/36196752?tool=bestpractice.com
Isocitrate dehydrogenase (IDH)-mutant gliomas are the second most common malignant brain tumors, with an annual incidence of 0.7 per 100,000. Incidence increases with age and peaks between 30 and 34 years for diffuse astrocytoma, IDH-mutant; and between 40 and 44 years for oligodendroglioma, IDH-mutant, 1p/19q codeleted.[7]Miller JJ, Gonzalez Castro LN, McBrayer S, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 Jan 5;25(1):4-25.
https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noac207/6761148
http://www.ncbi.nlm.nih.gov/pubmed/36239925?tool=bestpractice.com
Diffuse histone 3 (H3) mutant gliomas are rare, with an annual incidence of approximately 0.2 cases per 100,000 people. The median age at diagnosis for diffuse midline glioma H3 K27M-altered is between 7 and 8 years, while the median age at diagnosis for diffuse hemispheric glioma H3 G34-mutant is between 15 and 19 years.[8]World Health Organization. Central nervous system tumours: WHO classification of tumours. 5th ed. vol 6. Lyon, France: IARD Press; 2021.